Background: Our study addresses the pressing need for safe and effective treatments for pneumonia in young children caused by respiratory syncytial virus (RSV) and bacterial co-infections. This issue is particularly urgent given the absence of targeted RSV therapies and the growing threat of antibiotic resistance associated with managing bacterial co-infections. Methods: We conducted a double-blind, randomized clinical trial (ClinicalTrials.gov: NCT05929599) at Vietnam National Children’s Hospital to evaluate nasal-spraying Bacillus spore probiotics (LiveSpo Navax containing B. subtilis ANA4 and B. clausii ANA39 at ≥1 billion CFU/mL) in children aged 1-24 months with pneumonia due to RSV and bacterial co-infection. Participants were randomly assigned in a 1:1 ratio to receive standard care plus either LiveSpo Navax or physiological saline solution, using a simple sealed-number draw at enrollment. Primary outcomes were the median duration required to resolve common pneumonia symptoms, duration of oxygen therapy, and total treatment days. Results: A total of 120 children are enrolled (60 per group). In the final analysis, 50 participants in the Control group and 51 in the Navax group are included. The trial is completed with no serious adverse events or treatment-related side effects in either group. Navax treatment shortens the duration of eight symptoms associated with RSV pneumonia by one day, oxygen therapy by two days, and overall treatment by one day. Conclusions: The nasal-spraying Bacillus spore approach presents a safe, effective, and fast treatment for young children with pneumonia due to RSV and bacterial co-infections, making it especially a promising strategy for resource-limited settings.
This paper discusses an algorithm for constructing mixed-level screening designs (MLSDs) by augmenting some columns of a definitive screening designs (DSDs) with additional two-level columns. The constructed designs have the quadratic effects being orthogonal to main effects. The algorithm is used to construct designs with the number of runs being equal to p (i.e., the number of model parameters) for even p or p + 1 for odd p. The performance of these small DSD-based MLSDs in terms of the D-efficiency is evaluated against the 60 small MLSDs of Yang et al. (2014).
Several industrial experiments are set up using second-order split-plot designs (SPDs). These experiments have two types of factors: whole-plot (WP) factors and subplot (SP) factors. WP factors, also called hard-to-change factors, are factors for which levels are hard or expensive to change. SP factors, also called easy-to-change factors, are factors for which levels are easy or less expensive to change. In a split-plot experiment, the WP factors are confounded with blocks. Certain SPDs possess the equivalent-estimation property. For SPDs with this property, ordinary least-squares estimates of the model parameters are equivalent to the generalized least-squares estimates. This paper describes a fast and simple algorithm that produces D-efficient equivalent-estimation SPDs by interchanging the levels of the SP factors within each WP. The performance of this algorithm is evaluated against the 111 SPD scenarios reported in Macharia and Goos (2010) and Jones and Goos (2012).
1 March 2020 in Chemometrics and Intelligent Laboratory Systems
Allopurinol (ALP) is commonly used as a drug for gout treatment. However, ALP is known to cause cutaneous adverse reactions (CARs) in patients. The HLA-B*58:01 allele is considered a biomarker of severe CAR (SCAR) in patients with gout, with symptoms of Stevens Johnson syndrome, and with toxic epidermal necrolysis. However, in patients with gout and mild cutaneous adverse drug reactions (MCARs), the role of HLA-allele polymorphisms has not been thoroughly investigated. In this study, 50 samples from ALP-tolerant patients and ALP-induced MCARs patients were genotyped in order to examine the polymorphisms of their HLA-A and HLA-B alleles. Our results showed that the frequencies of HLA-A*02:01/HLA-A*24:02 and HLA-A*02:01/HLA-A*29:01, the dual haplotypes in HLA-A, in patients with ALP-induced MCARs were relatively high, at 33.3% (7/21), which was HLA-B*58:01-independent, while the frequency of these dual haplotypes in the HLA-A locus in ALP-tolerant patients was only 3.45% (1/29). The HLA-B*58:01 allele was detected in 38% (8/21) of patients with ALP-induced MCARs, and in 3.45% (1/29) of ALP-tolerant patients. Notably, although HLA-B*58:01 may be a cause for the occurrence of MCARs in patients with gout, this correlation was not as strong as that previously reported in patients with SCAR. In conclusion, in addition to the HLA-B*58:01 allele, the presence of the dual haplotypes of HLA-A*02:01/HLA-A*24:02 and/or HLA-A*02:01/HLA-A*29:01 in the HLA-A locus may also play an important role in the appearance of ALP-induced MCARs in the Vietnamese population. The obtained primary data may contribute to the development of suitable treatments for patients with gout not only in Vietnam but also in other Asian countries.
1 February 2014 in Statistics & Probability Letters